Alkem Laboratories, a pharmaceutical company, to acquire a 100% stake in Adroit Biomed, a pharmaceutical company with a focus on the skincare segment, for around ₹140 crore. Also, Alkem’s subsidiary Alkem MedTech to acquire a 100% stake in Bombay Ortho Industries, a manufacturer of orthopaedic implants, for around ₹147 crore.
Adroit has a differentiated dermatology portfolio with the key brands being Glutone, SkinFay, Racine and FortiSil. Adroit had a revenue of ₹53.55 crore in the financial year ended March 2024.
Alkem intends to complete the acquisition of Adroit by April 1, 2025, and the acquisition of Bombay Ortho by June 30, 2025, subject to customary closing conditions.
Mr B.N. Singh, Chairman, Alkem, said, “The acquisition of Adroit will enable Alkem to diversify its portfolio, enhance market penetration, and strengthen presence in the growing segments of dermatology and cosmetology. Also, our investment in Bombay Ortho is in line with our strategy for Medtech in India.”
Sandeep Singh, Managing Director, Alkem, said, “Medtech is a fast-growing space in India and the patient need for quality products is high. Through our acquisitions in the medical devices segment, we aim to meet the growing demand for implants in India.”
